Showing 3431-3440 of 5773 results for "".
- Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-completes-enrollment-ahead-of-schedule-in-its-phase-12a-trial-of-ea-2353-for-retinitis-pigmentosa/2481594/Endogena Therapeutics has announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stag
- Johnson & Johnson Vision to Present and Support 43 Company-Sponsored and Investigator-Led Studies at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-and-support-43-company-sponsored-and-investigator-led-studies-at-ascrs/2481593/Johnson & Johnson Vision will present and support 43 company-sponsored and investigator-led studies evaluating innovation, outcomes and satisfaction rates across its surgical portfolio at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, May 5-8
- FDA Clears Centricity Vision’s ZEPTOLink IOL Positioning Systemhttps://modernod.com/news/fda-clears-centricity-visions-zeptolink-iol-positioning-system/2481592/Centricity Vision announced it has received 510(k) clearance from the FDA for the ZEPTOLink IOL Positioning System. The new platform integrates the ZEPTO precision pulse capsulotomy technology with any phacoemulsification system to streamline cataract surgery.
- Alcon Expands Plastic Bank Partnership in 2023 to Further Support Sustainability Effortshttps://modernod.com/news/alcon-expands-plastic-bank-partnership-in-2023-to-further-support-sustainability-efforts/2481591/Alcon announced the expansion of the partnership with Plastic Bank—an organization that builds recycling ecosystems in under-developed communities to fight plastic pollution while providing collection members with a path out of poverty. For each ton of plastic introduced in the marketp
- Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 ASCRShttps://modernod.com/news/sight-sciences-glaucoma-and-dry-eye-technologies-to-be-featured-in-multiple-clinical-presentations-at-the-2023-ascrs/2481590/Sight Sciences announced that two of its proprietary glaucoma and dry eye technologies, the Omni Surgical System and the TearCare System, will be featured in oral presentations and one poster at this year's ASCRS annual meeting in San Diego. The Omni Surgical System technology
- Zeiss to Present New Surgical Workflow Innovations at ASCRShttps://modernod.com/news/zeiss-to-present-new-surgical-workflow-innovations-at-ascrs/2481589/Zeiss will showcase new surgical workflow innovations at the American Society of Cataract and Refractive Surgery (ASCRS) annual conference from May 6-8, 2023, in San Diego. These products as part of the Zeiss Medical Ecosystem help enhance ophthalmic care within the cataract and corneal refr
- Harrow Launches Recently Acquired Products Ilevro, Nevanec, and Maxidex in the UShttps://modernod.com/news/harrow-launches-recently-acquired-products-ilevro-nevanec-and-maxidex-in-the-us/2481587/Harrow announced the completion of the transfer to Harrow of the new drug applications (NDAs) for Ilevro (nepafenac ophthalmic suspension) 0.3%, Nevanec (nepafenac ophthalmic suspension) 0.1%, and Maxidex (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalm
- Alcon Names Daniel M. Miller, MD, PhD, Senior Scientific Advisor to Alcon's R&D team PDFhttps://modernod.com/news/alcon-names-daniel-m-miller-md-phd-senior-scientific-advisor-to-alcons-rd-team-pdf/2481584/Alcon announced that the highly esteemed ophthalmologist, Daniel M. Miller, MD, PhD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Miller is a fellowship-trained medical and surgical retina specialist. He will serve as a Senior Scientific Advisor to Alc
- Nanoscope Therapeutics Presents Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of RP at ARVOhttps://modernod.com/news/nanoscope-therapeutics-presents-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-rp-at-arvo/2481583/Nanoscope Therapeutics announced the presentation of key data from its phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARV
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand